Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript

Derek Maetzold: Yeah, thank you. We did reiterate our 2025 long term targets and indicated we expect to be able to achieve those without SEC as part of part of our business. But having said that, again, we do think that the evidence is very strong, and so we would certainly hope to have a better outcome than that.

Operator: I can confirm, we have no further questions on the line, so I’d like to hand it back to Derek for any final remarks.

Derek Maetzold: Thank you, operator. This concludes our second quarter 2023 earnings call. We thank you again for joining us today and for your continued interest in Castle Biosciences. Have a great evening.

Operator: Thank you all for joining today’s call. You may now go, connect your lines, and please enjoy the rest of your day.